Onchocerciasis is an eye and skin disease. Symptoms are caused by the microfilariae, which move around the human body in the subcutaneous tissue.
Prevalence of river blindness across the globe is rising. According to Pan American Health Organization, globally it is estimated that there are 18 million people infected and 270,000 blinded by onchocerciasis. It is one of the leading causes of blindness in many African countries. Government is focused on strengthening the healthcare sector and aid in lowering the infection percentage. High spending by the government of developing countries on healthcare infrastructure for adoption of new treatment is expected to drive the growth of global onchocerciasis treatment market. South Africa healthcare spending on health per capita for 2018 was US$ 526, a 5.82% increase from 2017. In 2016, Australia spent 44.1% of health expenditure on hospitals, the 15th highest, slightly above OECD median of 43.6% between 2000 and 2016.
Major medicine manufacturer are investing high for the development of new drugs their approach towards introduction new products in order to attract new customers is expected to augment the market growth. Regulatory bodies are focused on catering the medicinal needs as neglected tropical diseases are endemic in low and middle-income countries and their access to advanced medicine is limited. Approvals for new medicinal development and funding for R&D activities is expected to impact the growth of market. In 2018, Food and Drug Administration (FDA) approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older1. Collaborative development by the MDGH and TDR for development and achieving FDA approval is a critically important milestone. In 2021, Open Orphan PLC, a CRO pharmaceutical services company signed a strategic contract with AbbVie. The contract is to supply consultancy services to support a Phase II trial in Onchocerciasis Disease, an infectious disease commonly known as river blindness. This contract is expected to help company enhance the business. Major players are focused on shifting the manufacturing units to developing countries due to easy availability of raw material and low cost labor. In addition, favorable business policies by the developing countries and emergence of small & mid-size enterprises with innovative solutions are factors expected to boost the growth of target market. Factors such as high cost associated to new drug R&D activities and stringent government regulations related to product approval are expected to hamper the growth of global onchocerciasis treatment market. In addition, lack of developed infrastructure for R&D activities in middle income countries is expected to challenge the growth of target market. However, high investment by major players for R&D activities, rising awareness activities by the government and increasing spending on healthcare infrastructure development are factors expected to create new opportunities for players operating in the onchocerciasis treatment market over the forecast period. In addition, increasing public-private partnership for R&D activities and introduction of new products is expected to support the revenue transaction of target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global onchocerciasis treatment market due to high government spending on healthcare sector. Noticeable increase in patients suffering from eye associated issues, availability of developed medical infrastructure for R&D activities and presence of large number of players operating in the country are factors expected to support the growth of target market in this region. In addition, major players approach towards business expansion through acquisitions is expected to boost the market growth.
The global onchocerciasis treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Global Onchocerciasis Treatment Market
2017 – 2028
2021 – 2028
Treatment, Drug, Route Of Administration, End Use, Distribution Channel, and Geography
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Onchocerciasis Treatment Market Segment Analysis, 2019
The global onchocerciasis treatment market is segmented into treatment, drug, route of administration, end use, and distribution channel. The treatment segment is bifurcated into medication, supportive care, and surgery. Among treatment, the medication segment is expected to account for major revenue share in the global onchocerciasis treatment market. The distribution channel segment is divided into hospital pharmacy, retail pharmacy, and others. Among distribution channel the hospital pharmacy segment is expected to account for significant revenue share in target market. Players profiled in the global onchocerciasis treatment market are Merck & Co., Inc., Mayne Pharma Group, Par Pharmaceutical Companies, Inc., Delta Pharma Ltd., Life Pharmaceutical Company, and Taj Pharmaceuticals Limited.
Market By Treatment
Market By Drugs
Market By Route Of Administration
Market By End Use
Market By Distribution Channel
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Factors such as high cost associated to new drug R&D activities and stringent government regulations related to product approval are expected to hamper the growth of global onchocerciasis treatment market.
Major medicine manufacturer are investing high for the development of new drugs their approach towards introduction new products in order to attract new customers is expected to augment the market growth.
In treatment the medication segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Merck & Co., Inc., Mayne Pharma Group, and Par Pharmaceutical Companies, Inc.
The North America is expected to account for major revenue share in the global market.